Schnell R C, Park K S, Davies M H, Merrick B A, Weir S W
Department of Pharmaceutical Sciences, College of Pharmacy, North Dakota State University, Fargo 58105.
Toxicol Appl Pharmacol. 1988 Aug;95(1):1-11. doi: 10.1016/s0041-008x(88)80002-4.
Experiments were undertaken to examine the ability of selenium to protect against acetaminophen-induced hepatotoxicity and to examine possible mechanisms for this protective effect. Pretreatment of male, Sprague-Dawley rats with sodium selenite (12.5 mumol Se/kg, ip) 24 hr prior to acetaminophen administration produced a significant protection against the hepatotoxic effects of acetaminophen as assessed by a decrease in the plasma appearance of alanine aminotransferase and aspartate aminotransferase activities following acetaminophen. This was accompanied by an increase in the hepatic glutathione levels in selenium-treated animals and an inhibition in the decrease in hepatic glutathione content observed in animals receiving hepatotoxic doses of acetaminophen. Selenium pretreatment decreased the in vivo covalent binding of acetaminophen metabolites to hepatic protein, but did not alter hepatic microsomal cytochrome P-450 content or NADPH cytochrome c reductase activity, suggesting that selenium does not significantly alter the metabolism of acetaminophen to reactive electrophilic metabolites by the cytochrome P-450-dependent mixed-function oxidase enzyme system. Selenium produced an increase in the activity of gamma-glutamylcysteine synthetase which may account for the increased glutathione availability in selenium-treated animals and increased the activities of glutathione S-transferase and glucose-6-phosphate dehydrogenase. Examination of the urinary metabolite profile in selenium-treated animals revealed that the urinary excretion of acetaminophen and its metabolites was significantly increased over a 72-hr period. The increase occurred in the AAP-glucuronide metabolite while parent AAP and AAP-sulfate were actually decreased in selenium-treated rats. No change in recovery was observed in the AAP-glutathione or AAP-mercapturate urinary metabolites. While the glutathione conjugating system is enhanced by selenium treatment, amelioration of acetaminophen toxicity is most likely the result of enhanced glucuronidation which effectively diverts the amount of acetaminophen to be converted by the cytochrome P-450 system to the toxic metabolite.
开展实验以研究硒预防对乙酰氨基酚诱导的肝毒性的能力,并探究这种保护作用的可能机制。在给雄性Sprague-Dawley大鼠腹腔注射对乙酰氨基酚前24小时,用亚硒酸钠(12.5 μmol硒/千克,腹腔注射)进行预处理,结果显示,通过对乙酰氨基酚给药后丙氨酸转氨酶和天冬氨酸转氨酶活性在血浆中的出现情况的降低来评估,硒对乙酰氨基酚的肝毒性作用有显著的保护作用。这伴随着硒处理动物肝脏中谷胱甘肽水平的升高,以及在接受肝毒性剂量对乙酰氨基酚的动物中观察到的肝脏谷胱甘肽含量降低受到抑制。硒预处理降低了对乙酰氨基酚代谢产物与肝脏蛋白的体内共价结合,但未改变肝脏微粒体细胞色素P-450含量或NADPH细胞色素c还原酶活性,这表明硒不会显著改变细胞色素P-450依赖性混合功能氧化酶系统将对乙酰氨基酚代谢为反应性亲电代谢产物的过程。硒使γ-谷氨酰半胱氨酸合成酶的活性增加,这可能解释了硒处理动物中谷胱甘肽可用性的增加,并增加了谷胱甘肽S-转移酶和葡萄糖-6-磷酸脱氢酶 的活性。对硒处理动物尿液代谢产物谱的检查显示,在72小时内,对乙酰氨基酚及其代谢产物的尿排泄量显著增加。这种增加发生在对乙酰氨基酚葡糖醛酸代谢产物中,而在硒处理的大鼠中,母体对乙酰氨基酚和对乙酰氨基酚硫酸盐实际上减少了。对乙酰氨基酚-谷胱甘肽或对乙酰氨基酚-巯基尿酸尿代谢产物的回收率没有变化。虽然硒处理增强了谷胱甘肽结合系统,但对乙酰氨基酚毒性的改善最可能是葡糖醛酸化增强的结果,葡糖醛酸化有效地将细胞色素P-450系统转化为有毒代谢产物的对乙酰氨基酚量转移了。